The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Motif Bio To Raise GBP600,000 Via Placing To Fund Major Restructure

Wed, 02nd Oct 2019 11:59

(Alliance News) - Motif Bio PLC on Wednesday said it intends to raise GBP600,000 through a 142.9 million share placing priced at 0.42 pence per share in order to fund its restructuring programme.

Shares in Motif were up 13% at 0.68p in London in late morning trade.

Motif will be holding a general meeting where shareholders will vote on the winding down or disposal of Motif's US subsidiary, Motif Biosciences Inc, and on the issue of placing shares at less than their 1 pence per share nominal value.

The placing is subject to the passing of these resolutions, as well as resolutions to make changes to Motif's articles of association and renew the firm's authority so that it can grant a warrant over 20% of it share capital to Hercules Capital Inc.

In 2017, Motif agreed up to USD20 million of debt financing from Hercules in two tranches. Motif drew down the first USD15.0 million tranche but did not meet the milestones for the second tranche of USD5.0 million. This was amended in February 2019 and in March the firm made USD7.5 million of early repayments.

A new deal has now been agreed, and was announced in its half-year report on Monday. Should shareholders approve a new agreement between the two companies, it has been decided that Hercules will relinquish its loan guarantee from Motif and relieve future obligations. Motif Biosciences Inc will then wind down operations and hire an advisor so it can sell its assets, including antibiotic iclaprim, ideally selling the drug to a firm who would commercialise it.

Hercules will then be given a perfected security interest in all Motif Biosciences Inc's intellectual property as well as a warrant for another 20% of Motif's shares an a 5 pence per share exercise price.

As a result, Motif would be "relieved of the liability and guarantee for the Hercules loan of approximately USD6.9 million".

Following this arrangement, Motif will become a cash shell under AIM rule 15, giving it six months to make a reverse acquisition or have its shares cancelled.

Should the capital raise not go ahead and the deal fail to gain shareholder support, then Motif will be forced to cease its operations and its shares would be suspended.

SP Angel Corporate Finance LLP is acting as bookrunner on the conditional placing.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
24 Oct 2019 10:31

UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped

UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped

Read more
10 Oct 2019 11:52

Motif Bio Meeting With US FDA Confirms Need For Another iclaprim Trial

Motif Bio Meeting With US FDA Confirms Need For Another iclaprim Trial

Read more
1 Oct 2019 17:09

Motif Bio To Become Cash Shell If Restructuring Proposals Accepted

Motif Bio To Become Cash Shell If Restructuring Proposals Accepted

Read more
2 Sep 2019 11:39

Motif Bio Delays Next Amortisation Date Of Hercules Loan Facility

(Alliance News) - Novel antibiotics-focused biopharmaceutical company Motif Bio PLC said Monday it has agreed with Hercules Capital Inc to postpone the next amortisation date for its loan and date

Read more
19 Aug 2019 10:46

WINNERS & LOSERS SUMMARY: IXICO Rises On Positive Outlook

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------J up 3.8%. The is

Read more
19 Aug 2019 09:29

Motif Bio Receives US State Funding For Iclaprim Listeria Study

(Alliance News) - Biopharmaceutical firm Motif Bio PLC said Monday that the US government will fund a study on the effectiveness of the iclaprim drug against listeria monocytogenes.Shares a

Read more
1 Aug 2019 11:43

Motif Bio Postpones Next Amortisation Date Of Hercules Loan Facility

(Alliance News) - Biopharmaceutical firm Motif Bio PLC said on Thursday has amended its loan agreement with Hercules Capital Inc, delaying the next amortisation date by one month to September a to

Read more
12 Jun 2019 18:16

Amphion Innovations To Work With Debt Providers To Refinance Facility

(Alliance News) - Amphion Innovations PLC said Wednesday its debt providers have told the company the excess value of the collateral does not meet the terms of an agreed facility between the in at

Read more
6 Jun 2019 10:47

WINNERS & LOSERS SUMMARY: Rolls Royce And L&G Rise On Pension Pact

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Rolls up

Read more
31 May 2019 15:32

Motif Bio Shareholders Reject Remuneration Report Resolution

LONDON (Alliance News) - Motif Bio PLC on Friday said that shareholders voted against approval of the company's remuneration report.At the clinical-stage biopharmaceutical firm's on

Read more
1 May 2019 10:46

Motif Bio to work with Lamellar on cystic fibrosis treatment possibility

(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with Lamellar Biomedical, under which Motif Bio would conduct an in vivo preclinical study evaluating iclaprim in combination with Lamellar's patented 'Lamellasome' technology.

Read more
1 May 2019 09:26

Motif Bio Shares Up On Agreement With Lamellar To Start Clinical Study

LONDON (Alliance News) - Shares rose in Motif Bio PLC on Wednesday as it signed an agreement with Lamellar Biomedical to study the combination of Motif's iclaprim with Lamellar's in the at

Read more
26 Apr 2019 14:09

Motif Bio Appoints Andrew Powell As Non-Executive Director

LONDON (Alliance News) - Motif Bio PLC, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, said Friday it has appointed Andrew Powell as non-executive has as

Read more
15 Apr 2019 10:50

Motif Bio 2018 Loss Narrows As Research Costs Fall Despite US Delay

LONDON (Alliance News) - Motif Bio PLC said Monday its 2018 loss narrowed significantly as research costs fell, despite an unexpected delay in its new drug application in the US.In 2018, to

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.